Dordaviprone: A First-in-Class ClpP Activator for H3 K27M-Mutant Gliomas
- Fay
- 2 hours ago
- 3 min read
Introduction
Diffuse midline gliomas (DMGs) harboring the H3 K27M mutation (now classified as H3 K27M-altered diffuse midline glioma) represent one of the most devastating diagnoses in neuro-oncology. These tumors, which arise in critical midline structures like the thalamus and brainstem (e.g., DIPG), predominantly affect children and young adults. Historically, they have been uniformly fatal, with radiation therapy offering only transient palliative benefit and chemotherapy proving largely ineffective due to the blood-brain barrier (BBB) and the unique biology of the tumor.
Dordaviprone (ONC201), recently granted accelerated approval by the FDA under the brand name Modeyso, represents a historic turning point. As a first-in-class small molecule imipridone, it introduces a completely novel mechanism of action to oncology: the hyper-activation of mitochondrial proteases to induce cancer cell death.
Mechanism of Action: The "Mitochondrial Shredder"
Dordaviprone’s discovery was serendipitous. Originally identified in a phenotypic screen for compounds that upregulate the tumor suppressor TRAIL (TNF-related apoptosis-inducing ligand), its precise molecular target remained elusive for years. We now know it functions through a unique dual mechanism that targets the metabolic and signaling vulnerabilities of glioma cells.
ClpP Activation (Primary Mechanism): Dordaviprone is an allosteric agonist of Caseinolytic Protease P (ClpP), a mitochondrial serine protease. Under normal conditions, ClpP is tightly regulated. Dordaviprone binds to ClpP and hyper-activates it, causing the enzyme to open its proteolytic chamber indiscriminately. This leads to the uncontrolled degradation of essential mitochondrial respiratory chain proteins. The result is a catastrophic collapse of mitochondrial function, severe energy starvation, and the induction of apoptosis in cancer cells.
Dopamine Receptor Antagonism: In addition to its mitochondrial effects, dordaviprone acts as an antagonist at dopamine receptors DRD2 and DRD3. Since dopamine signaling can drive proliferative RAS pathways in certain gliomas, blocking this receptor provides a secondary antiproliferative effect.
Clinical Efficacy: Prospective Data from ONC013 and ONC014
The clinical utility of dordaviprone was established through an integrated analysis of efficacy, specifically highlighted by data from two prospectively defined trial arms: ONC013 (adults) and ONC014 (pediatrics).
Adult Recurrent DMG (ONC013 Arm B): This Phase 2 arm enrolled 30 adults (median age 32) with recurrent H3 K27M-mutant diffuse midline glioma.
Objective Response: The Objective Response Rate (ORR) assessed by RANO-HGG criteria was 16.7% (5 partial responses).
Durability: While the response rate appears modest, the quality and duration of these responses were exceptional. The median Duration of Response (DOR) was 15.1 months (range 7.5 to not reached), significantly exceeding historical expectations for recurrent glioblastoma therapies.
Time to Response: Responses were not immediate, with a median time to response of 3.8 months, reflecting the drug's mechanism of inducing gradual metabolic cell death rather than immediate cytotoxicity.
Pediatric Recurrent DMG (ONC014 Arm F): This Phase 1 arm enrolled 11 pediatric patients.
Tumor Regression: One patient achieved a confirmed partial response with >95% tumor regression that was sustained for 8.5 months. Another patient experienced >50% regression but did not meet technical RANO criteria due to concurrent dexamethasone use.
Survival: The 12-month Overall Survival (OS) rate was 27.3%, a meaningful signal in a disease where progression typically leads to death within months.
Safety and Tolerability
A distinguishing feature of dordaviprone is its ability to cross the blood-brain barrier while maintaining a highly favorable safety profile, a rarity in neuro-oncology drugs.
Adverse Events: In the adult study (ONC013), only 3 patients experienced Grade ≥3 treatment-related adverse events (TR-AEs), and there were no treatment-related serious adverse events (TR-SAEs).
Pediatrics: Similarly, the pediatric cohort reported minimal toxicity, with only one Grade ≥3 TR-AE and no treatment discontinuations due to toxicity. The absence of severe marrow suppression or cumulative organ toxicity makes it an ideal candidate for combination strategies.
Conclusion
Dordaviprone validates a new therapeutic modality: ClpP-mediated mitochondrial proteolysis. By successfully targeting the H3 K27M mutation's metabolic dependencies, it offers the first durable responses seen in diffuse midline glioma. Its recent FDA accelerated approval marks a major turning point in neuro-oncology, shifting the paradigm from palliative care to targeted disease modification for this lethal brain cancer.
Sources
Assessed and Endorsed by the MedReport Medical Review Board
